Sartorius Aktiengesellschaft (SUVPF)
USD 224.0
(0.0%)
USD 224.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 543.2 Million EUR | -55.91% |
| 2022 | 1.13 Billion EUR | 54.38% |
| 2021 | 735.79 Million EUR | 40.56% |
| 2020 | 523.47 Million EUR | 47.06% |
| 2019 | 355.94 Million EUR | 22.0% |
| 2018 | 291.75 Million EUR | 16.27% |
| 2017 | 250.93 Million EUR | 2.17% |
| 2016 | 245.61 Million EUR | 25.76% |
| 2015 | 195.3 Million EUR | 49.17% |
| 2014 | 130.92 Million EUR | 5.78% |
| 2013 | 123.76 Million EUR | 0.51% |
| 2012 | 123.13 Million EUR | 31.07% |
| 2011 | 93.94 Million EUR | 23.03% |
| 2010 | 76.36 Million EUR | 213.7% |
| 2009 | 24.34 Million EUR | -52.69% |
| 2008 | 51.45 Million EUR | 0.99% |
| 2007 | 50.94 Million EUR | -3.65% |
| 2006 | 52.87 Million EUR | 49.66% |
| 2005 | 35.33 Million EUR | 26.05% |
| 2004 | 28.03 Million EUR | 186.52% |
| 2003 | 9.78 Million EUR | 22.92% |
| 2002 | 7.95 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 148 Million EUR | 2.92% |
| 2024 Q3 | 68.2 Million EUR | -53.92% |
| 2024 Q1 | 143.8 Million EUR | 115.27% |
| 2023 Q4 | 66.8 Million EUR | -16.5% |
| 2023 FY | 500.8 Million EUR | -55.91% |
| 2023 Q2 | 207.3 Million EUR | 4.64% |
| 2023 Q1 | 198.1 Million EUR | -2.32% |
| 2023 Q3 | 80 Million EUR | -61.41% |
| 2022 Q4 | 202.8 Million EUR | -36.61% |
| 2022 FY | 1.13 Billion EUR | 54.38% |
| 2022 Q1 | 369.5 Million EUR | 12050.61% |
| 2022 Q2 | 324.6 Million EUR | -12.15% |
| 2022 Q3 | 319.9 Million EUR | -1.45% |
| 2021 Q1 | 215.4 Million EUR | 81.08% |
| 2021 FY | 735.79 Million EUR | 40.56% |
| 2021 Q2 | 234.5 Million EUR | 8.87% |
| 2021 Q3 | 242.5 Million EUR | 3.41% |
| 2021 Q4 | 3.04 Million EUR | -98.75% |
| 2020 Q2 | 99.5 Million EUR | -2.83% |
| 2020 Q4 | 118.95 Million EUR | -20.38% |
| 2020 Q1 | 102.4 Million EUR | 28.24% |
| 2020 FY | 523.47 Million EUR | 47.06% |
| 2020 Q3 | 149.4 Million EUR | 50.15% |
| 2019 Q1 | 82.3 Million EUR | 19.18% |
| 2019 Q3 | 86.5 Million EUR | -2.7% |
| 2019 Q4 | 79.84 Million EUR | -7.69% |
| 2019 FY | 355.94 Million EUR | 22.0% |
| 2019 Q2 | 88.9 Million EUR | 8.02% |
| 2018 Q4 | 69.05 Million EUR | -10.43% |
| 2018 Q1 | 59.3 Million EUR | 41.72% |
| 2018 FY | 291.75 Million EUR | 16.27% |
| 2018 Q3 | 77.1 Million EUR | 14.22% |
| 2018 Q2 | 67.5 Million EUR | 13.83% |
| 2017 Q3 | 54.6 Million EUR | -6.51% |
| 2017 FY | 250.93 Million EUR | 2.17% |
| 2017 Q2 | 58.4 Million EUR | 0.34% |
| 2017 Q4 | 41.84 Million EUR | -23.37% |
| 2017 Q1 | 58.2 Million EUR | 56.29% |
| 2016 Q2 | 63.6 Million EUR | 16.7% |
| 2016 Q4 | 37.23 Million EUR | -36.23% |
| 2016 Q1 | 54.5 Million EUR | 89.81% |
| 2016 Q3 | 58.4 Million EUR | -8.18% |
| 2016 FY | 245.61 Million EUR | 25.76% |
| 2015 Q4 | 28.71 Million EUR | -50.15% |
| 2015 Q1 | 47.1 Million EUR | 221.55% |
| 2015 Q2 | 48.6 Million EUR | 3.18% |
| 2015 Q3 | 57.6 Million EUR | 18.52% |
| 2015 FY | 195.3 Million EUR | 49.17% |
| 2014 Q3 | 35.1 Million EUR | 4.78% |
| 2014 FY | 130.92 Million EUR | 5.78% |
| 2014 Q4 | 14.64 Million EUR | -58.27% |
| 2014 Q2 | 33.5 Million EUR | 27.38% |
| 2014 Q1 | 26.3 Million EUR | 5.54% |
| 2013 Q2 | 32.2 Million EUR | 12.2% |
| 2013 Q4 | 24.91 Million EUR | -9.05% |
| 2013 FY | 123.76 Million EUR | 0.51% |
| 2013 Q1 | 28.7 Million EUR | 7.67% |
| 2013 Q3 | 27.4 Million EUR | -14.91% |
| 2012 Q3 | 31.1 Million EUR | 17.36% |
| 2012 Q1 | 27 Million EUR | 5.27% |
| 2012 Q2 | 26.5 Million EUR | -1.85% |
| 2012 FY | 123.13 Million EUR | 31.07% |
| 2012 Q4 | 26.65 Million EUR | -14.29% |
| 2011 Q2 | 19.5 Million EUR | -10.96% |
| 2011 Q1 | 21.9 Million EUR | 12.94% |
| 2011 Q3 | 26.8 Million EUR | 37.44% |
| 2011 Q4 | 25.64 Million EUR | -4.3% |
| 2011 FY | 93.94 Million EUR | 23.03% |
| 2010 Q1 | 13.9 Million EUR | 37.04% |
| 2010 Q4 | 19.39 Million EUR | -0.05% |
| 2010 FY | 76.36 Million EUR | 213.7% |
| 2010 Q2 | 17.2 Million EUR | 23.74% |
| 2010 Q3 | 19.4 Million EUR | 12.79% |
| 2009 Q2 | -3.2 Million EUR | -138.55% |
| 2009 Q1 | 8.3 Million EUR | 0.0% |
| 2009 Q4 | 10.14 Million EUR | -12.56% |
| 2009 Q3 | 11.6 Million EUR | 462.5% |
| 2009 FY | 24.34 Million EUR | -52.69% |
| 2008 FY | 51.45 Million EUR | 0.99% |
| 2007 FY | 50.94 Million EUR | -3.65% |
| 2006 FY | 52.87 Million EUR | 49.66% |
| 2005 FY | 35.33 Million EUR | 26.05% |
| 2004 FY | 28.03 Million EUR | 186.52% |
| 2003 FY | 9.78 Million EUR | 22.92% |
| 2002 FY | 7.95 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| American Medical Technologies Inc. | 1.16 Million USD | -46557.848% |
| Ansell Limited | 129.3 Million USD | -320.108% |
| Ansell Limited | 129.3 Million USD | -320.108% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 31.13 Million USD | -1644.482% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | -1.59 Million USD | 34141.465% |
| Psykey, Inc. | -797.5 Thousand USD | 68212.511% |
| ConvaTec Group Plc | 262.7 Million USD | -106.776% |
| ConvaTec Group Plc | 262.7 Million USD | -106.776% |
| Encision Inc. | -640.78 Thousand USD | 84871.288% |
| Golden Valley Development, Inc | -141.81 Thousand USD | 383147.74% |
| Hear AtLast Holdings, Inc. | -109.93 Thousand USD | 494232.63% |
| Innovative MedTech Inc. | -4.27 Million USD | 12809.18% |
| LifePoint, Inc. | -7.49 Million USD | 7347.278% |
| Medite Cancer Diagnostics, Inc. | -6.48 Million USD | 8482.716% |
| Paradigm Medical Industries, Inc. | 330 Thousand USD | -164506.061% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | -122.89 Thousand USD | 442121.32% |
| Reflect Scientific, Inc. | -467.27 Thousand USD | 116347.715% |
| SmileDirectClub, Inc. | -241.15 Million USD | 325.248% |
| Sector 10, Inc. | -39.84 Thousand USD | 1363416.936% |
| Shandong Weigao Group Medical Polymer Company Limited | 319.6 Million USD | -69.959% |
| SheerVision, Inc. | 155.72 Thousand USD | -348717.795% |
| United Health Products, Inc. | -2.42 Million USD | 22485.793% |
| Vasamed, Inc. | 4.74 Million USD | -11354.353% |
| Wearable Health Solutions, Inc. | -2.29 Million USD | 23777.708% |
| Yubo International Biotech Limited | -1.2 Million USD | 45170.497% |